What to look for in the upcoming gene therapy pipeline
As the gene therapy landscape continues to evolve, plan sponsors should familiarize themselves with the tools and strategies necessary to navigate the future of these game-changing treatments.
Read MoreClinically Speaking: Boosting Biosimilars Competition and Savings
An Evernorth analysis estimates that biosimilar competition can deliver $225 billion to $375 billion in drug cost savings for plan sponsors by 2031. Learn strategies to capture these savings, while pr...
Read MoreComprehensive coverage for building families
A comprehensive fertility benefit goes beyond a limited fertility benefit in terms of costs, outcomes, and employee happiness.
Read MoreMoving beyond the rebate debate to meaningfully and effectively lower prescription drug costs
Drug prices, not rebates, are the root of the problem
Read MoreHelping plans and patients get life-changing gene therapies
Gene therapies offer hope where none existed before, but health plans and employers need the right strategy to make these cutting-edge medications affordable and available.
Read MoreCopay Assistance Strategy Reduces Financial Burdens for Plans And Patients
Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs
Read MoreUnderserved Communities at Greater Risk for Non-adherence to Diabetes Medication
Evernorth Geographic Social Determinants Index (EGSDI) identifies opportunities for proactive patient and community engagement for individuals diagnosed with type 2 diabetes.
Read MoreDesigning plans to manage comorbid conditions
Health plans that address and manage complex chronic conditions such as cardiovascular disease, obesity, and diabetes have a competitive advantage.
Read MoreThree Ways to Help Your Members Avoid Interrupted Fertility Treatment
A well-designed fertility benefit helps members stay on treatment, reducing wasted dollars
Read MoreNew Express Scripts app feature gives customers easy, secure access to digital COVID vaccination record
Read More